Compare
HeartSciences Inc. vs Terawulf Inc. vs OppFi Inc. vs Burford Capital Ltd
| Latest fiscal year | HeartSciences Inc. HSCS | Terawulf Inc. WULF | OppFi Inc. OPFI | Burford Capital Ltd BUR |
|---|---|---|---|---|
| Year ended | 2026-04-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.3K | $168.46M | $381.18M | $413.36M |
| Revenue growth (YoY) | -0.7% | +20.3% | +18.6% | -24.3% |
| Gross margin | 59.1% | 39.2% | n/a | n/a |
| Operating margin | n/m | -110.5% | 43.7% | 56.2% |
| Net margin | n/m | -392.6% | 38.4% | 15.1% |
| Net income | -$9.14M | -$661.42M | $146.25M | $62.57M |
| EPS (Diluted) | n/a | -$1.66 | $0.99 | $0.28 |
| Operating cash flow | -$7.43M | -$123.18M | $401.31M | -$29.01M |
| Free cash flow | -$7.43M | -$1.18B | $382.19M | -$29.30M |
| Cash & equivalents | $1.70M | $3.27B | $49.45M | $566.44M |
| Total assets | n/a | $6.56B | $754.09M | $6.64B |
| Total liabilities | n/a | $6.42B | $445.21M | $3.51B |
| Shareholders' equity | $226.1K | $140.44M | $58.48M | $3.13B |
| Return on year-end equity | n/m | -470.9% | 250.1% | 2.0% |
| Shares outstanding | n/a | 420.07M | n/a | 218.90M |
Revenue, most recent five fiscal years
| Fiscal year | HeartSciences Inc. | Terawulf Inc. | OppFi Inc. | Burford Capital Ltd |
|---|---|---|---|---|
| Latest | $4.3K Ended 2026-04-30 | $168.46M Ended 2025-12-31 | $381.18M Ended 2025-12-31 | $413.36M Ended 2025-12-31 |
| 1 year earlier | $4.3K Ended 2025-04-30 | $140.05M Ended 2024-12-31 | $321.48M Ended 2024-12-31 | $546.09M Ended 2024-12-31 |
| 2 years earlier | $18.6K Ended 2024-04-30 | $69.23M Ended 2023-12-31 | $273.18M Ended 2023-12-31 | $1.09B Ended 2023-12-31 |
| 3 years earlier | $5.2K Ended 2023-04-30 | $15.03M Ended 2022-12-31 | $216.96M Ended 2022-12-31 | $319.23M Ended 2022-12-31 |
| 4 years earlier | $14.4K Ended 2022-04-30 | n/a | $263.68M Ended 2021-12-31 | $217.33M Ended 2021-12-31 |